<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883386</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00152719</org_study_id>
    <nct_id>NCT03883386</nct_id>
  </id_info>
  <brief_title>Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use</brief_title>
  <official_title>Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      G-CSF causes a release of histamine that may be a cause of chronic bone pain. Loratadine&#xD;
      targets histamine, and so may be effective in reducing bone pain.The researchers plan to&#xD;
      prospectively assess the effectiveness of loratadine for chronic bone pain in patients with&#xD;
      chronic G-CSF use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Severity Scores as Measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
    <description>The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. The questions ask participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where &quot;0&quot; indicates &quot;No pain&quot; and &quot;10&quot; indicates &quot;Pain as bad as you can imagine.&quot;&#xD;
Modified BPI: Included the pain intensity subscale, it is a Numerical Rating Scale with 4 questions (3-6): each item is ranked where 0 is no pain - 10 the worst pain.&#xD;
The Modified BPI will be measured on Days 2, 4, and 6. The full BPI will be measured on Day 7. On day 7 only responses from questions 3-6 will be analyzed for this outcome and a mean composite score for Days 2, 4, 6, and 7 will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Interference in Patients as Measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
    <description>Brief Pain Inventory (BPI) asks the participant to rate how their pain interferes with daily activities where &quot;0&quot; indicates &quot;does not interfere and &quot;10&quot; indicates &quot;completely interferes&quot;. The Pain Intensity Scale scores (Numerical Rating Scale (NRS)) for 7 questions: general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life from (BPI question 9A-G); 0 no life interference - 10 complete interference. Pain interference will be assessed on day 7 of each week.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Bone Pain</condition>
  <arm_group>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Take treatment daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Take placebo daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loratadine</intervention_name>
    <description>10 mg in a capsule</description>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
    <other_name>Claritin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered via capsule</description>
    <arm_group_label>Loratadine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neutropenia&#xD;
&#xD;
          -  Granulocyte-colony stimulating factor (G-CSF) use for at least 3 months at least 4&#xD;
             times per month&#xD;
&#xD;
          -  Mean bone pain of at least a 2/10 as assessed by questions 3-6 of the Brief Pain&#xD;
             Inventory (BPI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other sources of chronic pain&#xD;
&#xD;
          -  Previously tried loratadine for 7 consecutive days or more for bone pain&#xD;
&#xD;
          -  Allergy to loratadine&#xD;
&#xD;
          -  Chronic daily usage of antihistamine without an acceptable alternative&#xD;
             non-antihistamine medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Walkovich</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <results_first_submitted>September 28, 2020</results_first_submitted>
  <results_first_submitted_qc>September 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Kelly Walkovich</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics and Communicable Diseases</investigator_title>
  </responsible_party>
  <keyword>Granulocyte-colony stimulating factor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03883386/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Loratadine First</title>
          <description>Take treatment daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
        <group group_id="P2">
          <title>Placebo First</title>
          <description>Take placebo daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Assignment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Surveys Begun</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout and Second Assignment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loratadine First</title>
          <description>Take treatment daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
        <group group_id="B2">
          <title>Placebo First</title>
          <description>Take placebo daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="22" upper_limit="55"/>
                    <measurement group_id="B2" value="60" lower_limit="60" upper_limit="60"/>
                    <measurement group_id="B3" value="46" lower_limit="22" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Severity Scores as Measured by the Brief Pain Inventory (BPI)</title>
        <description>The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. The questions ask participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where &quot;0&quot; indicates &quot;No pain&quot; and &quot;10&quot; indicates &quot;Pain as bad as you can imagine.&quot;&#xD;
Modified BPI: Included the pain intensity subscale, it is a Numerical Rating Scale with 4 questions (3-6): each item is ranked where 0 is no pain - 10 the worst pain.&#xD;
The Modified BPI will be measured on Days 2, 4, and 6. The full BPI will be measured on Day 7. On day 7 only responses from questions 3-6 will be analyzed for this outcome and a mean composite score for Days 2, 4, 6, and 7 will be calculated.</description>
        <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
        <population>Because only one participant completed an on-treatment survey, the data is not analyzable for any comparative purpose and therefore was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Loratadine</title>
            <description>Take treatment daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Take placebo by capsule daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Severity Scores as Measured by the Brief Pain Inventory (BPI)</title>
          <description>The Brief Pain Inventory (BPI) rapidly assesses the severity of pain and its impact on functioning. The questions ask participants to rate their pain in the prior 24-hours OR prior 7-day on a 0 to 10 Numerical Rating Scale (NRS), where &quot;0&quot; indicates &quot;No pain&quot; and &quot;10&quot; indicates &quot;Pain as bad as you can imagine.&quot;&#xD;
Modified BPI: Included the pain intensity subscale, it is a Numerical Rating Scale with 4 questions (3-6): each item is ranked where 0 is no pain - 10 the worst pain.&#xD;
The Modified BPI will be measured on Days 2, 4, and 6. The full BPI will be measured on Day 7. On day 7 only responses from questions 3-6 will be analyzed for this outcome and a mean composite score for Days 2, 4, 6, and 7 will be calculated.</description>
          <population>Because only one participant completed an on-treatment survey, the data is not analyzable for any comparative purpose and therefore was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Interference in Patients as Measured by the Brief Pain Inventory (BPI)</title>
        <description>Brief Pain Inventory (BPI) asks the participant to rate how their pain interferes with daily activities where &quot;0&quot; indicates &quot;does not interfere and &quot;10&quot; indicates &quot;completely interferes&quot;. The Pain Intensity Scale scores (Numerical Rating Scale (NRS)) for 7 questions: general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life from (BPI question 9A-G); 0 no life interference - 10 complete interference. Pain interference will be assessed on day 7 of each week.</description>
        <time_frame>Week 1 (baseline week), week 2 (placebo or loratadine), and week 4 (placebo or loratadine).</time_frame>
        <population>Because only one participant completed an on-treatment survey, the data is not analyzable for any comparative purpose and therefore was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Loratadine</title>
            <description>Take treatment daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Take placebo by capsule daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Interference in Patients as Measured by the Brief Pain Inventory (BPI)</title>
          <description>Brief Pain Inventory (BPI) asks the participant to rate how their pain interferes with daily activities where &quot;0&quot; indicates &quot;does not interfere and &quot;10&quot; indicates &quot;completely interferes&quot;. The Pain Intensity Scale scores (Numerical Rating Scale (NRS)) for 7 questions: general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life from (BPI question 9A-G); 0 no life interference - 10 complete interference. Pain interference will be assessed on day 7 of each week.</description>
          <population>Because only one participant completed an on-treatment survey, the data is not analyzable for any comparative purpose and therefore was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 weeks' following was planned; 2 weeks was the longest anyone actually participated.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loratadine First</title>
          <description>Take treatment daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
        <group group_id="E2">
          <title>Placebo First</title>
          <description>Take placebo daily for 7 days.&#xD;
Loratadine: 10 mg in a capsule&#xD;
Placebo: Administered via capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Professor Kelly Walkovich</name_or_title>
      <organization>University of Michigan Medical School</organization>
      <phone>734-647-2893</phone>
      <email>kwalkovi@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

